We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Exicure Inc is a clinical-stage biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA ... Exicure Inc is a clinical-stage biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology. Show more
American International Group (NYSE:AIG) – AIG has appointed Keith Walsh as Executive Vice President and Chief Financial Officer, effective October 21. Walsh brings over 20 years of...
Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel (“Panel”) granted an extension to...
Exicure, Inc. (Nasdaq: XCUR, the “Company”) announced today that it has entered into an agreement with plaintiffs to settle Colwell v. Exicure, Inc. et al., Case No. 1:21-CV-06637, a previously...
Exicure, Inc. (Nasdaq: XCUR, “the Company”) today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Company...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.855 | -23.489010989 | 3.64 | 3.74 | 2.65 | 57231 | 3.118712 | CS |
4 | 1.055 | 60.9826589595 | 1.73 | 5.05 | 1.44 | 2543805 | 2.83600524 | CS |
12 | 0.985 | 54.7222222222 | 1.8 | 5.05 | 1.44 | 2963588 | 2.85151309 | CS |
26 | 0.075 | 2.76752767528 | 2.71 | 5.05 | 1.44 | 1539701 | 2.79974556 | CS |
52 | -0.665 | -19.2753623188 | 3.45 | 5.05 | 1.44 | 1031580 | 2.84894738 | CS |
156 | -3.015 | -51.9827586207 | 5.8 | 16.2 | 0.423 | 2657174 | 1.37120101 | CS |
260 | -9.215 | -76.7916666667 | 12 | 19.2 | 0.423 | 1834892 | 2.55563413 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions